Celcuity, Inc. (NASDAQ:CELC) Receives $47.40 Consensus Target Price from Analysts

Key Points

• Celcuity, Inc. (NASDAQ:CELC) has been rated with a consensus recommendation of "Buy" by five brokerages, with an average 12-month target price of $47.40.
• Director David Dalvey recently sold 100,000 shares at an average price of $43.98, reducing his ownership by 44.44% to 125,000 shares.
• Institutional investors currently own 63.33% of Celcuity's stock, with significant increases in positions from several firms, including BNP Paribas Financial Markets and Tower Research Capital LLC.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) has been assigned an average rating of "Buy" from the five ratings firms that are covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is $50.60.

CELC has been the subject of a number of recent research reports. HC Wainwright lifted their price objective on shares of Celcuity from $50.00 to $66.00 and gave the company a "buy" rating in a research note on Monday. Stifel Nicolaus started coverage on shares of Celcuity in a research note on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price objective for the company. Leerink Partners boosted their price target on shares of Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a research report on Monday, July 28th. Finally, Needham & Company LLC reduced their price target on shares of Celcuity from $74.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, August 15th.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the completion of the sale, the director directly owned 125,000 shares of the company's stock, valued at approximately $5,497,500. The trade was a 44.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 15.77% of the stock is owned by company insiders.

Institutional Trading of Celcuity

Several hedge funds have recently added to or reduced their stakes in CELC. BNP Paribas Financial Markets lifted its stake in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock worth $35,000 after purchasing an additional 1,167 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Celcuity by 49.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after acquiring an additional 1,132 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Celcuity in the fourth quarter valued at about $50,000. Tower Research Capital LLC TRC increased its position in shares of Celcuity by 211.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock valued at $74,000 after acquiring an additional 3,766 shares during the period. Finally, AlphaQuest LLC increased its position in shares of Celcuity by 176.3% in the second quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock valued at $95,000 after acquiring an additional 4,522 shares during the period. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Performance

Shares of CELC stock traded down $0.45 during trading on Friday, hitting $48.77. The company's stock had a trading volume of 1,124,957 shares, compared to its average volume of 2,929,614. The company has a market cap of $2.07 billion, a PE ratio of -14.14 and a beta of 0.68. The company has a current ratio of 4.58, a quick ratio of 6.61 and a debt-to-equity ratio of 2.24. The business has a fifty day moving average of $24.67 and a 200-day moving average of $15.56. Celcuity has a 52 week low of $7.57 and a 52 week high of $53.85.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.14). As a group, research analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.